MYMD-1, MyMD Pharmaceuticals’ lead candidate for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting…
Articles by Joana Carvalho, PhD
The University of South Florida (USF) received a $1 million donation to fund research focused on finding ways to detect…
Galapagos and Gilead Sciences have suspended the worldwide ISABELA Phase 3 program investigating the potential of oral ziritaxestat…
Lung cancer is more likely in people with idiopathic pulmonary fibrosis (IPF) than the public at large, and these…
A researcher at the Fred Hutchinson Cancer Research Center received the first $50,000 award of a new funding program jointly…
The European Idiopathic Pulmonary Fibrosis (IPF) and Related Disorders Federation (EU-IPFF) is welcoming patients, clinicians, researchers, industry representatives, and policymakers…
People with idiopathic pulmonary fibrosis (IPF) in poorer health are less likely than healthier patients to tolerate more than…
A set of rare, disease-causing variants in genes that help control both the body’s immune response and cell adhesion —…
Owlstone Medical has launched a new breath biomarker panel test — a “breathalyzer for disease” — to distinguish different…
People with idiopathic pulmonary fibrosis (IPF) who have had a collapsed lung, a condition known as pneumothorax, are at…